Bremer Trust National Association Reduces Position in Johnson & Johnson (JNJ)

Bremer Trust National Association lowered its stake in Johnson & Johnson (NYSE:JNJ) by 5.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,248 shares of the company’s stock after selling 1,160 shares during the quarter. Bremer Trust National Association’s holdings in Johnson & Johnson were worth $2,690,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Beach Investment Management LLC. boosted its stake in shares of Johnson & Johnson by 1,256.6% during the 2nd quarter. Beach Investment Management LLC. now owns 286,648 shares of the company’s stock worth $37,921,000 after acquiring an additional 265,518 shares during the last quarter. First Mercantile Trust Co. boosted its stake in shares of Johnson & Johnson by 2.3% during the 2nd quarter. First Mercantile Trust Co. now owns 15,113 shares of the company’s stock worth $1,999,000 after acquiring an additional 344 shares during the last quarter. BTC Capital Management Inc. boosted its stake in shares of Johnson & Johnson by 1.4% during the 2nd quarter. BTC Capital Management Inc. now owns 53,183 shares of the company’s stock worth $7,038,000 after acquiring an additional 712 shares during the last quarter. Traynor Capital Management Inc. boosted its stake in shares of Johnson & Johnson by 10.8% during the 2nd quarter. Traynor Capital Management Inc. now owns 10,454 shares of the company’s stock worth $1,369,000 after acquiring an additional 1,015 shares during the last quarter. Finally, Keystone Financial Planning Inc. boosted its stake in shares of Johnson & Johnson by 1.6% during the 2nd quarter. Keystone Financial Planning Inc. now owns 32,969 shares of the company’s stock worth $4,361,000 after acquiring an additional 529 shares during the last quarter. Institutional investors own 67.21% of the company’s stock.

How to Become a New Pot Stock Millionaire

Johnson & Johnson (NYSE:JNJ) opened at $125.10 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41. Johnson & Johnson has a one year low of $120.95 and a one year high of $148.32. The firm has a market cap of $335,631.06, a price-to-earnings ratio of 320.77, a P/E/G ratio of 1.99 and a beta of 0.77.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The company had revenue of $20.20 billion for the quarter, compared to analysts’ expectations of $20.08 billion. During the same quarter in the previous year, the company earned $1.58 EPS. Johnson & Johnson’s revenue for the quarter was up 11.5% on a year-over-year basis. research analysts expect that Johnson & Johnson will post 8.11 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th were issued a $0.84 dividend. The ex-dividend date was Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.69%. Johnson & Johnson’s dividend payout ratio is currently 861.54%.

JNJ has been the topic of several analyst reports. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price target on the stock in a research note on Thursday, January 11th. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Jefferies Group set a $165.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Monday, February 26th. Stifel Nicolaus lifted their price target on shares of Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research note on Wednesday, January 24th. Finally, Zacks Investment Research cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Tuesday, December 12th. Four analysts have rated the stock with a sell rating, nine have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $146.06.

In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of Johnson & Johnson stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the sale, the vice president now directly owns 357,906 shares in the company, valued at approximately $46,477,673.16. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.19% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Bremer Trust National Association Reduces Position in Johnson & Johnson (JNJ)” was published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3301216/bremer-trust-national-association-reduces-position-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$3.95 Billion in Sales Expected for Kohl’s  This Quarter
$3.95 Billion in Sales Expected for Kohl’s This Quarter
$0.50 EPS Expected for Bitauto Hldg Ltd  This Quarter
$0.50 EPS Expected for Bitauto Hldg Ltd This Quarter
Inogen  Expected to Post Quarterly Sales of $62.60 Million
Inogen Expected to Post Quarterly Sales of $62.60 Million
Steem  Trading Up 13.1% Over Last Week
Steem Trading Up 13.1% Over Last Week
BitAsean  Market Capitalization Achieves $88,048.00
BitAsean Market Capitalization Achieves $88,048.00
C R Bard  Earns Coverage Optimism Rating of 0.16
C R Bard Earns Coverage Optimism Rating of 0.16


© 2006-2018 Ticker Report. Google+.